查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物反应器市场：产业趋势和到 2035 年的全球预测 - 依製造材料、生物製程、生物产品、关键地区划分
市场调查报告书
商品编码
1479827

生物反应器市场：产业趋势和到 2035 年的全球预测 - 依製造材料、生物製程、生物产品、关键地区划分

Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material, Type of Bioprocess, Type of Biologic, and Key Geographical Regions
出版日期: | 出版商: Roots Analysis | 英文 224 Pages | 商品交期: 最快1-2个工作天内

价格

生物反应器市场规模预计到 2024 年将达到 167 亿美元，并预计在 2024-2035 年预测期内复合年增长率为 11.1%。

生物反应器是一种用于上游生物製造的专用容器，可在精确控制的条件下促进细胞和组织的生长。 这些条件包括温度、pH、压力、通气和营养水平等因素，旨在优化活细胞和细胞组成的环境。 主要目标是促进底物转化为多种生物产品。 这些产品范围从疫苗、融合蛋白、抗体、激素、白细胞介素和□等治疗蛋白到基于细胞和寡核甘酸的治疗药物、用于基因治疗的逆转录病毒载体，以及模仿3D 组织结构的2D和先进体外模型。 一般来说，这些生物反应器是圆柱形的，通常由不銹钢製成，尺寸从毫升到几公升不等，适合不同的生物过程需求和操作模式。

全球对生物製药的需求迅速成长，大大推动了生物製程用品市场的成长。 随着公司建立自己的生物製药生产设施或将生产外包给专业机构，对临床和商业规模生物反应器的需求正在迅速增加。 目前估计全球生物反应器产能超过 1,300 万公升，包括内部生产和外包生产。 由于这种巨大的需求，生物反应器市场已发展成为一个竞争激烈的舞台，许多活跃的公司在设计、工程和製造各种应用的生物反应器方面拥有专业知识。 我们提供的产品范围从传统的不銹钢生物反应器到一次性/一次性生物反应器、搅拌罐生物反应器、小型生物反应器、气升式生物反应器、灌註生物反应器、泡罩塔生物反应器和光生物反应器。

本报告调查了全球生物反应器市场，并概述了市场概况、製造材料、生物工艺、生物产品、地区以及进入市场的公司概况。

目录

第一章前言

第 2 章执行摘要

第 3 章简介

第四章生物反应器製造商：市场状况

第五章企业竞争力分析

  • 章节概述
  • 假设/主要参数
  • 调查方法
  • 企业竞争力分析：中小企业
  • 企业竞争力分析：中型企业
  • 企业竞争力分析：大型企业与超大型企业

第六章公司简介

  • 章节概述
  • Applikon Biotechnology
  • Bionet
  • Cytiva
  • Eppendorf
  • Merck
  • Ollital Technology
  • Parr Instrument Company
  • Sartorius
  • Shanghai Bailun Biological Technology
  • Solaris Biotech（acquired by Donaldson Company）
  • Solida Biotech
  • Zhengzhou Laboao Instrument Equipment（LABAO）

第七章能力分析

第 8 章案例研究：生物製程控制器与自动化系统

第九章市场预测

  • 章节概述
  • 主要假设与预测研究方法
  • 2023-2035 年全球生物反应器市场：依製造材料划分
  • 全球玻璃生物反应器市场，2023-2035
  • 全球不锈钢生物反应器市场，2023-2035
  • 2023-2035 年全球一次性生物反应器市场
  • 2023-2035 年全球生物反应器市场：依生物製程划分

第 10 章高阶主管见解

第11章结论

第 12 章附录 1：表格资料

第十三章附录2：公司与组织名单

Product Code: RAU1027

Bioreactors Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Fabrication Material (Glass, Stainless Steel and Single use), Type of Bioprocess (Batch, Fed-batch and Continuous), Type of Biologic (Antibodies, Vaccines, Cell Therapies and Other Biologics), and Key Geographical Regions (North America, Europe, Asia-Pacific, and Rest of the World)

The Bioreactors Market is valued at USD 16.7 billion in 2024 growing at a CAGR of 11.1% during the forecast period 2024-2035.

Bioreactors represent specialized vessels employed in upstream biomanufacturing to foster the growth of cells and tissues under precisely controlled conditions. These conditions encompass factors like temperature, pH, pressure, aeration, and nutrient levels, all aimed at optimizing the environment for live cells or cellular components. The primary goal is to facilitate the conversion of substrates into a diverse array of biological products. These products span from therapeutic proteins such as vaccines, fusion proteins, antibodies, hormones, interleukins, and enzymes to cutting-edge medicinal products like cell-based and oligonucleotide-based therapies, retroviral vectors for gene therapy, and sophisticated in vitro models mimicking 2D and 3D tissue constructs, essential for drug discovery research. Typically, these bioreactors, often cylindrical and made of stainless steel, vary in size from milliliters to several liters, tailored to different bioprocessing needs and operational modes.

The surge in global demand for biopharmaceutical products has significantly propelled the growth of the bioprocessing supplies market. As companies either establish their own biopharmaceutical manufacturing facilities or opt to outsource production to specialized organizations, the demand for clinical and commercial-scale bioreactors has skyrocketed. Current estimates, including both in-house and outsourced capacities, indicate a global bioreactors capacity exceeding 13 million liters. Given this immense demand, the bioreactors market has evolved into a competitive arena, featuring numerous active companies boasting expertise in designing, engineering, and manufacturing a wide spectrum of bioreactors tailored to diverse applications. Offerings range from traditional stainless-steel bioreactors to disposable/single-use bioreactors, stirred-tank bioreactors, small-scale bioreactors, air lift bioreactors, perfusion bioreactors, bubble column bioreactors, and photobioreactors.

Key Market Segments

Fabrication Material

Stainless Steel

Single Use

Glass

Type of Bioprocess

Batch and Fed-batch

Continuous

Type of Biologic

Antibodies

Vaccines

Cell Therapies

Other Biologics

Key Geographical Regions

North America

Europe

Asia-Pacific

Rest of the World

Research Coverage:

A comprehensive analysis of the overall market landscape of companies manufacturing bioreactors, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, geographical reach (North America, Europe, Asia-Pacific and Rest of the World), capacity (micro-mini, small-scale, bench-scale, lab-scale, pilot-scale and large-scale), scale of operation (preclinical, clinical and commercial), scalability, type of bioprocess (batch, fed-batch and continuous), type of cell culture (2D cell culture, 3D cell culture and 4D cell culture), mode of operation (manual, semi-automatic and automatic) and type of end user (academic institutes and research laboratories, biopharmaceutical and pharmaceutical industries, contract manufacturing organizations, and contract research organizations).

Comprehensives company competitiveness analysis of bioreactor manufacturers based on manufacturer strength (in terms of years of experience and company size), portfolio strength (considering geographical reach, number of products in portfolio, type of bioreactor, capacity, scale of operation, scalability, type of bioprocess, type of cell culture, mode of operation and end users).

Comprehensive company profiles of leading players manufacturing bioreactors (shortlisted on the basis of cumulative strength of manufacturers and product portfolio); each profile includes a brief overview of the company, along with information on its financial information (if available), product portfolio, recent developments and an informed future outlook.

A projection of the global installed capacity of bioreactors for biologics, compiled from data sourced from various publicly available industry outlets. This estimation also includes a breakdown of the available capacity categorized by fabrication material (glass, stainless steel, and single-use), cell culture source (mammalian, microbial, and others), reactor volume (less than 2,000 L, 2,000 to 5,000 L, 5,001 to 10,000 L, and over 10,000 L), manufacturer type (in-house, hybrid, and Contract Manufacturing Organizations [CMOs]), and major geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

A case study on the market landscape of bioprocess controllers and automation systems, providing information on scale of operation (laboratory, clinical, and commercial), key features (scalability / ease to use, visual data display, remote accessibility, built-in system control sensors, expansive I/O compatibility and provisions for alarms / alerts), compatibility with bioreactor system (stirred tank (glass), single use bioreactor, stirred tank (steel), rocking motion), type of bioprocess (batch, fed-batch and perfusion), and type of process controlled (cell cultivation and microbial fermentation). In addition, the chapter presents details of companies involved in the development of bioprocess control software, upstream and downstream controllers, including information on their year of establishment, company size, and location of headquarters.

A comprehensive market forecast analysis has been conducted to assess the current market size and future prospects for the bioreactors market over the coming 11 years. Utilizing multiple parameters and anticipated adoption trends, coupled with primary validations, we have developed informed estimates for market size within the forecast period spanning from 2024 to 2035. This chapter presents detailed projections of both current and future opportunities within the market, segmented across various factors including fabrication material (glass, stainless steel, and single-use), bioprocess type (batch, fed-batch, and continuous), types of biologics (such as antibodies, vaccines, cell therapies, and other biologics), and key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World).

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the Bioreactors Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

Applikon Biotechnology

Bionet

Cytiva

Eppendorf

Merck

Ollital Technology

Parr Instrument Company

Sartorius

Shanghai Bailun Biological Technology

Solaris Biotech

Solida Biotech

Zhengzhou Laboao Instrument Equipment (LABAO)

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Bioreactors
  • 3.3. Components of a Bioreactor
  • 3.4. Types of Bioreactors
    • 3.4.1. Classification based on Type of Bioprocess
    • 3.4.2. Classification based on Mode of Action
  • 3.5. Applications of Bioreactors
  • 3.6. Future Perspectives

4. BIOREACTOR MANUFACTURERS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Bioreactor Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Region of Headquarters
    • 4.2.4. Analysis by Location of Headquarters
    • 4.2.5. Analysis by Year of Establishment and Region of Headquarters
    • 4.2.6. Analysis by Company Size and Region of Headquarters
    • 4.2.7. Analysis by Year of Establishment, Company Size and Region of Headquarters
    • 4.2.8. Analysis by Geographical Reach
    • 4.2.9. Analysis by Region of Headquarters and Geographical Reach
    • 4.2.10. Analysis by Capacity
    • 4.2.11. Analysis by Scale of Operation
    • 4.2.12. Analysis by Scalability
    • 4.2.13. Analysis by Type of Bioprocess
    • 4.2.14. Analysis by Type of Cell Culture
    • 4.2.15. Analysis by Mode of Operation
    • 4.2.16. Analysis by Type of End-user

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions / Key Parameters
  • 5.3. Methodology
  • 5.4. Company Competitiveness Analysis: Small Companies
    • 5.4.1. Company Competitiveness Analysis: Small Companies based in North America
    • 5.4.2. Company Competitiveness Analysis: Small Companies based in Europe
    • 5.4.3. Company Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
  • 5.5. Company Competitiveness Analysis: Mid-sized Companies
    • 5.5.1. Company Competitiveness Analysis: Mid-sized Companies based in North America
    • 5.5.2. Company Competitiveness Analysis: Mid-sized Companies based in Europe
    • 5.5.3. Company Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
  • 5.6. Company Competitiveness Analysis: Large and Very Large Companies

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Applikon Biotechnology (acquired by Getinge)
    • 6.2.1. Company Overview
    • 6.2.2. Product Portfolio
    • 6.2.3. Recent Developments and Future Outlook
  • 6.3. Bionet
    • 6.3.1. Company Overview
    • 6.3.2. Product Portfolio
    • 6.3.3. Recent Developments and Future Outlook
  • 6.4. Cytiva
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Product Portfolio
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Eppendorf
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Product Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Merck
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Product Portfolio
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Ollital Technology
    • 6.7.1. Company Overview
    • 6.7.2. Product Portfolio
    • 6.7.3. Recent Developments and Future Outlook
  • 6.8. Parr Instrument Company
    • 6.8.1. Company Overview
    • 6.8.2. Product Portfolio
    • 6.8.3. Recent Developments and Future Outlook
  • 6.9. Sartorius
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Product Portfolio
    • 6.9.4. Recent Developments and Future Outlook
  • 6.10. Shanghai Bailun Biological Technology
    • 6.10.1. Company Overview
    • 6.10.2. Product Portfolio
    • 6.10.3. Recent Developments and Future Outlook
  • 6.11. Solaris Biotech (acquired by Donaldson Company)
    • 6.11.1. Company Overview
    • 6.11.2. Product Portfolio
    • 6.11.3. Recent Developments and Future Outlook
  • 6.12. Solida Biotech
    • 6.12.1. Company Overview
    • 6.12.2. Product Portfolio
    • 6.12.3. Recent Developments and Future Outlook
  • 6.13. Zhengzhou Laboao Instrument Equipment (LABAO)
    • 6.13.1. Company Overview
    • 6.13.2. Product Portfolio
    • 6.13.3. Recent Developments and Future Outlook

7. CAPACITY ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Key Assumptions and Methodology
    • 7.2.1 Bioreactors s: Global Installed Capacity of Biologics
      • 7.2.1.1. Analysis by Fabrication Material
      • 7.2.1.2. Analysis by Source of Cell Culture
      • 7.2.1.3. Analysis by Reactor Volume
      • 7.2.1.4. Analysis by Type of Manufacturer
      • 7.2.1.5. Analysis by Key Geographical Regions
  • 7.3. Concluding Remarks

8. CASE STUDY: BIOPROCESS CONTROLLERS AND AUTOMATION SYSTEMS

  • 8.1. Chapter Overview
  • 8.2. Bioprocess Control Software: Overall Market Landscape
    • 8.2.1. Analysis by Scale of Operation
    • 8.2.2. Analysis by Key Features
    • 8.2.3. Analysis by Compatibility with System
    • 8.2.4. Analysis by Type of Process Controlled
  • 8.3. Bioprocess Control Software Developers: Overall Market Landscape
    • 8.3.1. Analysis by Year of Establishment
    • 8.3.2. Analysis by Company Size
    • 8.3.3. Analysis by Location of Headquarters
  • 8.4. Upstream Controllers: Overall Market Landscape
    • 8.4.1. Analysis by Scale of Operation
    • 8.4.2. Analysis by Key Features
    • 8.4.3. Analysis by Compatibility with Bioreactor System
    • 8.4.4. Analysis by Type of Bioprocess
    • 8.4.5. Analysis by Type of Process Controlled
  • 8.5. Upstream Controller Developers: Overall Market Landscape
    • 8.5.1. Analysis by Year of Establishment
    • 8.5.2. Analysis by Company Size
    • 8.5.3. Analysis by Location of Headquarters
  • 8.6. Downstream Controller Systems: Overall Market Landscape
    • 8.6.1. Analysis by Scale of Operation
    • 8.6.2. Analysis by Key Features
    • 8.6.3. Analysis by Type of System
    • 8.6.4. Analysis by Type of Bioprocess
    • 8.6.5. Analysis by Application Area
  • 8.7. Downstream Controller System Developers: Overall Market Landscape
    • 8.7.1. Analysis by Year of Establishment
    • 8.7.2. Analysis by Company Size
    • 8.7.3. Analysis by Location of Headquarters

9. MARKET FORECAST

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Forecast Methodology
  • 9.3. Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
  • 9.3. 1. Global Glass Bioreactors Market, 2023-2035
  • 9.3. 2. Global Stainless Steel Bioreactors Market, 2023-2035
  • 9.3. 3. Global Single use Bioreactors Market, 2023-2035
  • 9.4. Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
      • 9.3.3.1. Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
      • 9.3.3.2. Global Bioreactors Market for Continuous Process, 2023-2035
    • 9.3.4. Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
      • 9.3.4.1. Global Bioreactors Market for Antibodies, 2023-2035
      • 9.3.4.2. Global Bioreactors Market for Vaccines, 2023-2035
      • 9.3.4.3. Global Bioreactors Market for Cell Therapies, 2023-2035
      • 9.3.4.4. Global Bioreactors Market for Other Biologics, 2023-2035
    • 9.3.5. Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
      • 9.3.5.1. Global Bioreactors Market in North America, 2023-2035
      • 9.3.5.2. Global Bioreactors Market in Europe, 2023-2035
      • 9.3.5.3. Global Bioreactors Market in Asia-Pacific, 2023-2035
      • 9.3.5.4. Global Bioreactors Market in Rest of the World, 2023-2035

10. EXECUTIVE INSIGHTS

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Bioreactor Manufacturers: List of Companies
  • Table 4.2 Bioreactor Manufacturers: Information on Geographical Reach
  • Table 4.3 Bioreactor Manufacturers: Information on Volume and Type of Bioreactor
  • Table 4.4 Bioreactor Manufacturers: Information on Scale of Operation and Scalability
  • Table 4.5 Bioreactor Manufacturers: Type of Bioprocess and Type of Cell Culture
  • Table 4.6 Bioreactor Manufacturers: Information on Mode of Operation and Type of End-user
  • Table 6.1 Bioreactor Manufacturers: List of Profiled Companies
  • Table 6.2 Applikon Biotechnology: Company Snapshot
  • Table 6.3 Applikon Biotechnology: Bioreactor Portfolio
  • Table 6.4 Applikon Biotechnology: Recent Developments and Future Outlook
  • Table 6.5 Bionet: Company Snapshot
  • Table 6.6 Bionet: Bioreactor Portfolio
  • Table 6.7 Bionet: Recent Developments and Future Outlook
  • Table 6.8 Cytiva: Company Snapshot
  • Table 6.9 Cytiva: Bioreactor Portfolio
  • Table 6.10 Cytiva: Recent Developments and Future Outlook
  • Table 6.11 Eppendorf: Company Snapshot
  • Table 6.12 Eppendorf: Bioreactor Portfolio
  • Table 6.13 Eppendorf: Recent Developments and Future Outlook
  • Table 6.14 Merck: Company Snapshot
  • Table 6.15 Merck: Bioreactor Portfolio
  • Table 6.16 Merck: Recent Developments and Future Outlook
  • Table 6.17 Ollital Technology: Company Snapshot
  • Table 6.18 Ollital Technology: Bioreactor Portfolio
  • Table 6.19 Ollital Technology: Recent Developments and Future Outlook
  • Table 6.20 Parr Instrument Company: Company Snapshot
  • Table 6.21 Parr Instrument Company: Bioreactor Portfolio
  • Table 6.22 Parr Instrument Company: Recent Developments and Future Outlook
  • Table 6.23 Sartorius: Company Snapshot
  • Table 6.24 Sartorius: Bioreactor Portfolio
  • Table 6.25 Sartorius: Recent Developments and Future Outlook
  • Table 6.26 Shanghai Bailun Biological Technology: Company Snapshot
  • Table 6.27 Shanghai Bailun Biological Technology: Bioreactor Portfolio
  • Table 6.28 Shanghai Bailun Biological Technology: Recent Developments and Future Outlook
  • Table 6.29 Solaris Biotech: Company Snapshot
  • Table 6.30 Solaris Biotech: Bioreactor Portfolio
  • Table 6.31 Solaris Biotech: Recent Developments and Future Outlook
  • Table 6.32 Solida Biotech: Company Snapshot
  • Table 6.33 Solida Biotech: Bioreactor Portfolio
  • Table 6.34 Solida Biotech: Recent Developments and Future Outlook
  • Table 6.35 Zhengzhou Laboao Instrument Equipment (LABAO): Company Snapshot
  • Table 6.36 Zhengzhou Laboao Instrument Equipment (LABAO): Bioreactor Portfolio
  • Table 6.37 Zhengzhou Laboao Instrument Equipment (LABAO): Recent Developments and Future Outlook
  • Table 7.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
  • Table 7.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
  • Table 7.3 Capacity Analysis: Average Capacity for Mammalian Expression System (Sample Data Set)
  • Table 7.4 Capacity Analysis: Average Capacity for Microbial Expression System (Sample Data Set)
  • Table 7.5 Capacity Analysis: Global Distribution of Contract, in-house and Hybrid Biomanufacturing Capacity
  • Table 8.1 Bioprocess Control Software: Information on Key Features, Compatibility with Bioreactor System and Process Controlled
  • Table 8.2 Upstream Controllers: Information on Key Features, Type of Bioprocess and Compatibility with Bioreactor System
  • Table 8.3 Downstream Controller Systems: Information on Key Features, Type of System, Type of Bioprocess and Application Area
  • Table 10.1 Ensofa Projects: Key Highlights
  • Table 10.2 Sunrise Process Equipments: Key Highlights
  • Table 10.3 CerCell: Key Highlights
  • Table 10.4 CelVivo: Key Highlights
  • Table 12.1 Bioreactor Manufacturers: Distribution by Year of Establishment
  • Table 12.2 Bioreactor Manufacturers: Distribution by Company Size
  • Table 12.3 Bioreactor Manufacturers: Distribution by Region of Headquarters
  • Table 12.4 Bioreactor Manufacturers: Distribution by Location of Headquarters
  • Table 12.5 Bioreactor Manufacturers: Distribution by Year of Establishment and Region of Headquarters
  • Table 12.6 Bioreactor Manufacturers: Distribution by Company Size and Region of Headquarters
  • Table 12.7 Bioreactor Manufacturers: Distribution by Year of Establishment, Company Size and Region of Headquarters
  • Table 12.8 Bioreactor Manufacturers: Distribution by Geographical Reach
  • Table 12.9 Bioreactor Manufacturers: Distribution by Region of Headquarters Region and Geographical Reach
  • Table 12.10 Bioreactor Manufacturers: Distribution by Capacity
  • Table 12.11 Bioreactor Manufacturers: Distribution by Scale of Operation
  • Table 12.12 Bioreactor Manufacturers: Distribution by Scalability
  • Table 12.13 Bioreactor Manufacturers: Distribution by Type of Bioprocess
  • Table 12.14 Bioreactor Manufacturers: Analysis by Type of Cell Culture
  • Table 12.15 Bioreactor Manufacturers: Analysis by Mode of Operation
  • Table 12.16 Bioreactor Manufacturers: Analysis by Type of End-user
  • Table 12.17 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
  • Table 12.18 Eppendorf: Annual Revenues, FY 2017-FY 2021 (EUR Million)
  • Table 12.19 Merck: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
  • Table 12.20 Sartorius: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
  • Table 12.21 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Fabrication Material
  • Table 12.22 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Source of Cell Culture
  • Table 12.23 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Reactor Volume
  • Table 12.24 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Type of Manufacturer
  • Table 12.25 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Key Geographical Regions
  • Table 12.26 Bioprocess Control Software: Distribution by Scale of Operation
  • Table 12.27 Bioprocess Control Software: Distribution by Key Features
  • Table 12.28 Bioprocess Control Software: Distribution by Compatibility with Systems
  • Table 12.29 Bioprocess Control Software: Distribution by Type of Process Controlled
  • Table 12.30 Bioprocess Control Software Developers: Distribution by Year of Establishment
  • Table 12.31 Bioprocess Control Software Developers: Distribution by Company Size
  • Table 12.32 Bioprocess Control Software Developers: Distribution by Location of Headquarters
  • Table 12.33 Upstream Controllers: Distribution by Scale of Operation
  • Table 12.34 Upstream Controllers: Distribution by Key Features
  • Table 12.35 Upstream Controllers: Distribution by Compatibility with Bioreactor Systems
  • Table 12.36 Upstream Controllers: Distribution by Type of Bioprocess
  • Table 12.37 Upstream Controllers: Distribution by Type of Process Controlled
  • Table 12.38 Upstream Controller Developers: Distribution by Year of Establishment
  • Table 12.39 Upstream Controller Developers: Distribution by Company Size
  • Table 12.40 Upstream Controller Developers: Distribution by Location of Headquarters
  • Table 12.41 Downstream Controller Systems: Distribution by Scale of Operation
  • Table 12.42 Downstream Controller Systems: Distribution by Key Features
  • Table 12.43 Downstream Controller Systems: Distribution by Type of System
  • Table 12.44 Downstream Controller Systems: Distribution by Type of Bioprocess
  • Table 12.45 Downstream Controller Systems: Distribution by Application Area
  • Table 12.46 Downstream Controller System Developers: Distribution by Year of Establishment
  • Table 12.47 Downstream Controller System Developers: Distribution by Company Size
  • Table 12.48 Downstream Controller System Developers: Distribution by Location of Headquarters
  • Table 12.49 Global Bioreactors Market, 2023-2035 (USD Billion)
  • Table 12.50 Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
  • Table 12.51 Global Glass Bioreactors Market, 2023-2035
  • Table 12.52 Global Stainless Steel Bioreactors Market, 2023-2035
  • Table 12.53 Global Single use Bioreactors Market, 2023-2035
  • Table 12.54 Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
  • Table 12.55 Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
  • Table 12.56 Global Bioreactors Market for Continuous Process, 2023-2035
  • Table 12.57 Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
  • Table 12.58 Global Bioreactors Market for Antibodies, 2023-2035
  • Table 12.59 Global Bioreactors Market for Vaccines, 2023-2035
  • Table 12.60 Global Bioreactors Market for Cell Therapies, 2023-2035
  • Table 12.61 Global Bioreactors Market for Other Biologics, 2023-2035
  • Table 12.62 Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
  • Table 12.63 Bioreactors Market in North America, 2023-2035
  • Table 12.64 Bioreactors Market in Europe, 2023-2035
  • Table 12.65 Bioreactors Market in Asia-Pacific, 2023-2035
  • Table 12.66 Bioreactors Market in Rest of the World, 2023-2035

List of Figures

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Capacity Analysis
  • Figure 2.3 Executive Summary: Market Forecast
  • Figure 3.1 Components of a Bioreactor
  • Figure 3.2 Types of Bioreactors (based on Type of Bioprocess)
  • Figure 3.3 Types of Bioreactors (based on Mode of Action)
  • Figure 3.4 Industries Employing Bioreactors
  • Figure 3.5 Applications of Bioreactors in Pharmaceutical Industry
  • Figure 4.1 Bioreactor Manufacturers: Distribution by Year of Establishment
  • Figure 4.2 Bioreactor Manufacturers: Distribution by Company Size
  • Figure 4.3 Bioreactor Manufacturers: Distribution by Region of Headquarters
  • Figure 4.4 Bioreactor Manufacturers: Distribution by Location of Headquarters
  • Figure 4.5 Bioreactor Manufacturers: Distribution by Year of Establishment and Region of Headquarters
  • Figure 4.6 Bioreactor Manufacturers: Distribution by Company Size and Region of Headquarters
  • Figure 4.7 Bioreactor Manufacturers: Distribution by Year of Establishment, Company Size and Region of Headquarters
  • Figure 4.8 Bioreactor Manufacturers: Distribution by Geographical Reach
  • Figure 4.9 Bioreactor Manufacturers: Distribution by Region of Headquarters and Geographical Reach
  • Figure 4.10 Bioreactor Manufacturers: Distribution by Capacity
  • Figure 4.11 Bioreactor Manufacturers: Distribution by Scale of Operation
  • Figure 4.12 Bioreactor Manufacturers: Distribution by Scalability
  • Figure 4.13 Bioreactor Manufacturers: Distribution by Type of Bioprocess
  • Figure 4.14 Bioreactor Manufacturers: Distribution by Type of Cell Culture
  • Figure 4.15 Bioreactor Manufacturers: Distribution by Mode of Operation
  • Figure 4.16 Bioreactor Manufacturers: Distribution by Type of End-user
  • Figure 5.1 Competitiveness Analysis: Small Companies
  • Figure 5.2 Competitiveness Analysis: Small Companies based in North America
  • Figure 5.3 Competitiveness Analysis: Small Companies based in Europe
  • Figure 5.4 Competitiveness Analysis: Small Companies based in Asia-Pacific and Rest of the World
  • Figure 5.5 Competitiveness Analysis: Mid-sized Companies
  • Figure 5.6 Competitiveness Analysis: Mid-sized Companies based in North America
  • Figure 5.7 Competitiveness Analysis: Mid-sized Companies based in Europe
  • Figure 5.8 Competitiveness Analysis: Mid-sized Companies based in Asia-Pacific and Rest of the World
  • Figure 5.9 Competitiveness Analysis: Large and Very Large Companies
  • Figure 5.10 Competitiveness Analysis of Bioreactor Manufacturers: Competitiveness Score of Top Players
  • Figure 6.1 Cytiva: Annual Revenues, FY 2017-FY 2021 (USD Million)
  • Figure 6.2 Eppendorf: Annual Revenues, FY 2017-FY 2021 (EUR Million)
  • Figure 6.3 Merck: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
  • Figure 6.4 Sartorius: Annual Revenues, FY 2017-FY 2022 (EUR Billion)
  • Figure 7.1 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Fabrication Material
  • Figure 7.2 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Source of Cell Culture
  • Figure 7.3 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Reactor Volume
  • Figure 7.4 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Type of Manufacturer
  • Figure 7.5 Global Installed Bioreactors Capacity (by Million Liters): Distribution by Key Geographical Regions
  • Figure 8.1 Bioprocess Control Software: Distribution by Scale of Operation
  • Figure 8.2 Bioprocess Control Software: Distribution by Key Features
  • Figure 8.3 Bioprocess Control Software: Distribution by Compatibility with System
  • Figure 8.4 Bioprocess Control Software: Distribution by Type of Process Controlled
  • Figure 8.5 Bioprocess Control Software Developers: Distribution by Year of Establishment
  • Figure 8.6 Bioprocess Control Software Developers: Distribution by Company Size
  • Figure 8.7 Bioprocess Control Software Developers: Distribution by Location of Headquarters
  • Figure 8.8 Upstream Controllers: Distribution by Scale of Operation
  • Figure 8.9 Upstream Controllers: Distribution by Key Features
  • Figure 8.10 Upstream Controllers: Distribution by Compatibility with Bioreactor System
  • Figure 8.11 Upstream Controllers: Distribution by Type of Bioprocess
  • Figure 8.12 Upstream Controllers: Distribution by Type of Process Controlled
  • Figure 8.13 Upstream Controller Developers: Distribution by Year of Establishment
  • Figure 8.14 Upstream Controller Developers: Distribution by Company Size
  • Figure 8.15 Upstream Controller Developers: Distribution by Location of Headquarters
  • Figure 8.16 Downstream Controller Systems: Distribution by Scale of Operation
  • Figure 8.17 Downstream Controller Systems: Distribution by Key Features
  • Figure 8.18 Downstream Controller Systems: Distribution by Type of System
  • Figure 8.19 Downstream Controller Systems: Distribution by Type of Bioprocess
  • Figure 8.20 Downstream Controller Systems: Distribution by Application Area
  • Figure 8.21 Downstream Controller System Developers: Distribution by Year of Establishment
  • Figure 8.22 Downstream Controller System Developers: Distribution by Company Size
  • Figure 8.23 Downstream Controller System Developers: Distribution by Location of Headquarters
  • Figure 9.1 Global Bioreactors Market, 2023-2035 (USD Billion)
  • Figure 9.2 Global Bioreactors Market, 2023-2035: Distribution by Fabrication Material
  • Figure 9.3 Global Glass Bioreactors Market, 2023-2035
  • Figure 9.4 Global Stainless Steel Bioreactors Market, 2023-2035
  • Figure 9.5 Global Single use Bioreactors Market, 2023-2035
  • Figure 9.6 Global Bioreactors Market, 2023-2035: Distribution by Type of Bioprocess
  • Figure 9.7 Global Bioreactors Market for Batch and Fed-batch Process, 2023-2035
  • Figure 9.8 Global Bioreactors Market for Continuous Process, 2023-2035
  • Figure 9.9 Global Bioreactors Market, 2023-2035: Distribution by Type of Biologic
  • Figure 9.10 Global Bioreactors Market for Antibodies, 2023-2035
  • Figure 9.11 Global Bioreactors Market for Vaccines, 2023-2035
  • Figure 9.12 Global Bioreactors Market for Cell Therapies, 2023-2035
  • Figure 9.13 Global Bioreactors Market for Other Biologics, 2023-2035
  • Figure 9.14 Global Bioreactors Market, 2023-2035: Distribution by Key Geographical Regions
  • Figure 9.15 Bioreactors Market in North America, 2023-2035
  • Figure 9.16 Bioreactors Market in Europe, 2023-2035
  • Figure 9.17 Bioreactors Market in Asia-Pacific, 2023-2035
  • Figure 9.18 Bioreactors Market in Rest of the World, 2023-2035
  • Figure 11.1 Concluding Remarks: Overall Market Landscape of Bioreactor Manufacturers
  • Figure 11.2 Concluding Remarks: Geographical Distribution of Bioreactor Manufacturers
  • Figure 11.3 Concluding Remarks: Capacity Analysis
  • Figure 11.4 Concluding Remarks: Market Forecast